| Symbol | GALT |
|---|---|
| Name | GALECTIN THERAPEUTICS INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA 30071 |
| Telephone | 678-620-3186 |
| Fax | — |
| — | |
| Website | https://www.galectintherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001133416 |
| Description | Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis. Additional info from NASDAQ: |
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
Read more(90% Positive) GALECTIN THERAPEUTICS INC (GALT) Reports Q3 2026 Financial Results
Read moreGalectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet
Read moreJamil Khurram 🟡 adjusted position in 16.2K shares (1 derivative) of GALECTIN THERAPEUTICS INC (GALT) at $5.13 Transaction Date: Jul 14, 2026 | Filing ID: 000063
Read moreShlevin Harold H. 🟡 adjusted position in 30.0K shares (2 derivative) of GALECTIN THERAPEUTICS INC (GALT) at $5.04 Transaction Date: Jun 26, 2026 | Filing ID: 000061
Read moreJamil Khurram 🟡 adjusted position in 52.0K shares (3 derivative) of GALECTIN THERAPEUTICS INC (GALT) at $5.04 Transaction Date: Jun 26, 2026 | Filing ID: 000059
Read more📋 Harold Shlevin (Director) plans to sell 22K shares of GALECTIN THERAPEUTICS INCORPORATED (at $5.04 each, total $112K) Filed: Jun 29, 2026 | ID: 045997
Read more📋 Jamil Khurram (Officer) plans to sell 68K shares of GALECTIN THERAPEUTICS INC (at $5.00 each, total $341K) Filed: Jun 26, 2026 | ID: 000216
Read moreJamil Khurram 🟡 adjusted position in 7.6K shares (1 derivative) of GALECTIN THERAPEUTICS INC (GALT) at $3.14 Transaction Date: Jun 23, 2026 | Filing ID: 000057
Read more📋 Jamil Khurram (Officer) plans to sell 8K shares of GALECTIN THERAPEUTICS INC (at $3.14 each, total $26K) Filed: Jun 23, 2026 | ID: 000208
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT04365868 | Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Es… | Phase2 | Prevention of Esophageal Varices | Terminated | 2020-06-25 | 2025-04-10 | ClinicalTrials.gov |
| NCT04332432 | A Single-dose, Open-label, Pharmacokinetic Study of Belapectin (GR-MD-02) in Su… | Phase1 | Hepatic Impairment | Completed | 2020-06-16 | 2022-03-09 | ClinicalTrials.gov |
| NCT02575404 | GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamo… | Phase1 | Melanoma | Completed | 2016-05-16 | 2022-10-10 | ClinicalTrials.gov |
| NCT02421094 | Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis… | Phase2 | Nonalcoholic Steatohepatitis | Completed | 2015-09-01 | 2016-09-27 | ClinicalTrials.gov |
| NCT02407041 | An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for T… | Phase2 | Psoriasis | Completed | 2015-09-01 | 2018-03-01 | ClinicalTrials.gov |
| NCT02462967 | Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatm… | Phase2 | Hypertension, Portal | Completed | 2015-06-01 | 2017-10-01 | ClinicalTrials.gov |
| NCT02117362 | Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melano… | Phase1 | Metastatic Melanoma | Completed | 2014-05-08 | 2018-11-28 | ClinicalTrials.gov |
| NCT01899859 | Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Ste… | Phase1 | Non-Alcoholic Steatohepatitis (NASH) | Completed | 2013-07-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT00388700 | A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjec… | Phase2 | Colorectal Cancer | Withdrawn | 2006-10-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00386516 | Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Tr… | Phase2 | Cancer of the Bile Duct | Withdrawn | 2006-09-01 | 2009-06-01 | ClinicalTrials.gov |
| NCT00110721 | GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Co… | Phase2 | Colorectal Cancer | Terminated | 2005-05-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00054977 | Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors | Phase1 | Colorectal Cancer | Completed | 2003-02-01 | 2006-09-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | Prevention of Esophageal Varices | TERMINATED | NCT04365868 |
| belapectin | Other | Phase PHASE2 | Prevention of Esophageal Varices | TERMINATED | NCT04365868 |
| Placebo | Other | Phase PHASE1 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT01899859 |
| GR-MD-02 | Other | Phase PHASE1 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT01899859 |
| Ipilimumab | Other | Phase PHASE1 | Metastatic Melanoma | COMPLETED | NCT02117362 |
| 8 mg/kg GR-MD-02 | Other | Phase PHASE1 | Metastatic Melanoma | COMPLETED | NCT02117362 |
| 4 mg/kg GR-MD-02 | Other | Phase PHASE1 | Metastatic Melanoma | COMPLETED | NCT02117362 |
| 2 mg/kg GR-MD-02 | Other | Phase PHASE1 | Metastatic Melanoma | COMPLETED | NCT02117362 |
| 1 mg/kg GR-MD-02 | Other | Phase PHASE1 | Metastatic Melanoma | COMPLETED | NCT02117362 |
| GR-MD-02 | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT02407041 |
| Placebo | Other | Phase PHASE2 | Hypertension, Portal | COMPLETED | NCT02462967 |
| GR-MD-02 | Other | Phase PHASE2 | Hypertension, Portal | COMPLETED | NCT02462967 |
| Placebo | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis | COMPLETED | NCT02421094 |
| GR-MD-02 | Other | Phase PHASE2 | Nonalcoholic Steatohepatitis | COMPLETED | NCT02421094 |
| belapectin | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT04332432 |
| Pembrolizumab | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT02575404 |
| GR-MD-02 | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT02575404 |
| Placebo | Other | Phase PHASE2 | Prevention of Esophageal Varices | TERMINATED | NCT04365868 |
| belapectin | Other | Phase PHASE2 | Prevention of Esophageal Varices | TERMINATED | NCT04365868 |
| belapectin | DRUG | Phase PHASE2 | Prevention of Esophageal Varices | TERMINATED | NCT04365868 |
| Pembrolizumab | DRUG | Phase PHASE1 | Melanoma | COMPLETED | NCT02575404 |
| Ipilimumab | BIOLOGICAL | Phase PHASE1 | Metastatic Melanoma | COMPLETED | NCT02117362 |
| 8 mg/kg GR-MD-02 | BIOLOGICAL | Phase PHASE1 | Metastatic Melanoma | COMPLETED | NCT02117362 |
| 4 mg/kg GR-MD-02 | BIOLOGICAL | Phase PHASE1 | Metastatic Melanoma | COMPLETED | NCT02117362 |
| 2 mg/kg GR-MD-02 | BIOLOGICAL | Phase PHASE1 | Metastatic Melanoma | COMPLETED | NCT02117362 |
| 1 mg/kg GR-MD-02 | BIOLOGICAL | Phase PHASE1 | Metastatic Melanoma | COMPLETED | NCT02117362 |
| Placebo | DRUG | Phase PHASE2 | Prevention of Esophageal Varices | TERMINATED | NCT04365868 |
| GR-MD-02 | DRUG | Phase PHASE1 | Melanoma | COMPLETED | NCT02575404 |
| 5-Fluorouracil | DRUG | Phase PHASE2 | Cancer of the Bile Duct | WITHDRAWN | NCT00386516 |
| 5-fluorouracil | DRUG | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT00054977 |
| 5-Fluorouracil, Leukovorin, bevacizumab | DRUG | Phase PHASE2 | Colorectal Cancer | WITHDRAWN | NCT00388700 |
| GM-CT-01 | DRUG | Phase PHASE2 | Colorectal Cancer | WITHDRAWN | NCT00388700 |
| GM-CT-01 plus 5-Fluorouracil | DRUG | Phase PHASE2 | Colorectal Cancer | TERMINATED | NCT00110721 |